Multiple endocrine neoplasia type 2. Biological and clinical aspects;Neoplasie endocrine multiple. Aspetti biologici e clinici: Clinica e diagnostica della MEN 2

Minerva Chirurgica

Volumn 59, Issue 1, 2004, Pages 69-74

  Tagliabue, M ^a   Rossetto, R ^a   Cestino, L ^a   Palestini, N ^a  

^a Sezione di Chirurgia Generale   (Italy)

Author keywords

Multiple endocrine neoplasia, classification; Multiple endocrine neoplasia, diagnosis; Multiple endocrine neoplasia, etiology

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CATECHOLAMINE; METADRENALIN;

ASPIRATION BIOPSY; CALCITONIN BLOOD LEVEL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ECHOGRAPHY; ENDOCRINE DISEASE; GENE MUTATION; GENETIC DISORDER; HUMAN; HYPERCALCIURIA; HYPERPARATHYROIDISM; NEPHROLITHIASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; PROTO ONCOGENE; REVIEW; SCINTIGRAPHY; SIPPLE SYNDROME; THORAX RADIOGRAPHY; THYROID MEDULLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; TREATMENT OUTCOME; TUMOR LOCALIZATION;

HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A;

EID: 2442696316     PISSN: 00264733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-60.
2. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RB, Stelwagen T, Luo Y et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary carcinoma. Nature 1994;367:375-6.
3. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-71.
4. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJ et al. Genothipe-phenothype correlation in multiple endocrine neoplasia type 2: report of the International RET mutation Consortium. J Intern Med 1995;238:343-6.
5. Gagel RF, Levy ML, Donovan DT, Alford BR, Wheeler T, Tschen JA et al. Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med 1989;11:802-6.
6. Romeo G, Ceccherini I, Celli J, Priolo, Betsos N, Bonardi G et al. Association of multiple endocrine neoplasia type 2 and Hirschsprung disease. J Intern Med 1998;243:515-20.
7. Chong GC, Beahrs OH, Sizemore GW, Woolner LH et al. Medullary carcinoma of the thyroid gland. Cancer 1975;35:695-704.
8. Kane LA, Tsai MS, Gharib H, Khosla S, Robertson DM, Schaid DJ et al. Familial medullary thyroid cancer and prominent corneal nerves: clinical and genetic analysis. J Clin Endocrinol Metab 1995;80:289-93.
9. Duh QY, Sancho JJ, Greenspan FS, Hunt TK, Galante M, deLorimier AA et al. Medullary thyroid carcinoma. The need for early diagnosis and total thyroidectomy. Arch Surg 1989;124:1206-10.
10. Heshmati HM, Gharib H, van Heerden JA, Sizemore GW. Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J Med 1997;103:60-9.
11. Hazard JB, Hawk WA, Crile G. Medullary (solid) carcinoma of the thyroid: a clinicopathologic entity. J Clin Endocrinol Metab 1959;19:152-61.
12. Dunn JM, Taindon JR. Medullary thyroid carcinoma. Br J Surg 1993;80:6-9.
13. Modigliani E. Le cancer medullaire de la thyroide. Rev Med Interne 1999;20:490-503.
14. Tagliabue M, Pagani A, Palestini N, Manieri C, Martina V. Multiple endocrine neoplasia (MEN IIB) with Cushing's syndrome due to medullary thyroid carcinoma producing corticotropin-releasing hormone. Panminerva Medica 1996;38:41-4.
15. Heshmati HM, Hofbauer LC. Multiple endocrine neoplasia type 2: recent progress in diagnosis and management. Europ J Endocrinol 1997;137:572-8.
16. Gimm O, Sutter T, Drolle H. Diagnosis and therapy of sporadic and familial medullary thyroid carcinoma. J Cancer Res Clin Oncol 2001;127:156-65.
17. Hahm JR, Lee MS, Min YK, Lee MK, Kim KW, Nam SJ et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma on patients with nodular thyroid disease. Thyroid 2001;11:73-80.
18. Pacini F, Fontanelli M, Fugazzola L, Elisei R, Romei C, Di Coscio G et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1994;78:826-829.
19. Niccoli P, Wion-Barbot N, Caron P, Henry JF, de Micco C, Saint Andre JP et al. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. J Clin Endocrinol Metab 1997;82:338-41.
20. 111In-octreotide and 99mTc(V)-dimercaptosuccinic acid studies in the imaging of recurrent medullary thyroid carcinoma. J Endocrinol 1995;144:339-45.
21. Hoefnagel CA, Delprat CC, Zanin D, van der Schoot JB. New radionuclide tracers for the diagnosis and therapy of medullary thyroid carcinoma. Clin Nucl Med 1988;13:159-65.
22. Randolph GW. Medullary carcinoma of the thyroid. Cancer Control 2000;7:253-61.
23. Modigliani E, Vasen HM, Raue K, Dralle H, Frilling A, Gheri RG et al. Pheocromocitoma in multiple endocrine neoplasia type 2: European study. J Intern Med 1995;238:363-7.
24. Nguyen L, Niccoli-Sire P, Caron P, Bastie D, Maes B, Chabrier G et al. Pheochromocitoma in multiple endocrine neoplasia type 2: a prospective study. Eur J Endocrinol 2001;144:37-44.
25. Evans DB, Lee JE, Merrel RC, Hickey RC. Adrenal medullary disease in multiple endocrine neoplasia type 2. Appropriate management. Endocrinol Metab Clin North Am 1994;24:167-76.
26. Eisenhofer G, Keiser H, Friberg P, Mezey E, Huynh TT, Hiremagalu B et al. Plasma metanephrines are markers of pheocromocitoma produced by catechol-O-methyl-transferase within tumor. J Clin Endocrinol Metab 1998;83:2175-85.
27. Baudin E, Bidart JM, Bachelot A, Ducreux M, Elias D, Ruffle P et al. Impact of chomogranin A measurement in the work-up of neuroendocrine tumors. Ann Oncol 2001;12 (Suppl2):S79-82.
28. Raue F, Kraimps JL, Dralle H, Cougard P, Proye C, Frilling A et al. Primary hyperparthyroidism in multiple endocrine neoplasia type 2A. J Intern Med 1995;238:369-73.
29. Schuffenecker I, Virally-Monod M, Brohet R, Goldgar D, Conte-Devolx B, Leclerc L et al. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. J Clin Metab 1998;83:487-91.
30. Thomas PM, Gagel RF. Advances in genetic screening for multiple endocrine neoplasia type 2 and the implication for management of children at risk. Endocrinologist 1994;4:140-6.